Proyecto de Investigación Nacionales
Contrato Miguel Servet: Searching for potential predictive biomarkers for Immunotherapy.
Volver a proyectos01/01/2021 - 31/12/2025
Descripción
Characterizing the interaction of cancer cells with the host adaptive immune system is critical for understanding tumor immunology. As the key cellular effectors of adaptive immunity, T cells are endowed with specialized receptors (T Cell Receptor or TCR), to recognize and to eliminate cancer cells. The diversity of the TCR repertoire results from specialized genetic diversification mechanisms that generate an incredible variability allowing recognizing extensive collections of antigens. Based on the attainment and function of the TCR, the TCR repertoire is a mirror of the human immune response, and the dynamic changes of its usage can be assumed as a promising biomarker to monitor immunomodulatory therapies (Schrama et al 2017). Recent developments in high-throughput TCR sequencing have provided new insights into the clonal repertoire directed against tumor neoantigens, particularly in patients with high mutational burden cancers (Reuben et al 2017, Riaz et al 2017, Pasetto et al 2016). Based on these data, the present project will examine the immune repertoire previous to the treatment to determine its role on the response to immunotherapy. With this aim, TCR repertoire will be sequenced from the same liquid biopsies at the beginning of the immunotherapy to decipher its correlation with the response and with the TMB in blood.
Características
| Código | CP20/00188 |
|---|---|
| Fecha de inicio | 01/01/2021 |
| Fecha de finalización | 31/12/2025 |
| Investigador responsable | Mónica Martínez Fernández |
| Entidad financiación | Instituto de Salud Carlos III / FSE-FEDER |
| Importe financiación | 242.500,00 € |
